Clinical trials: Urologic Neoplasms, active
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other…
- Conditions
- Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT04413123
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bradley A. McGregor, MD
Bladder Cancer
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder…
- Trial name
- NEXT (NCT03171025)
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Utah
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Hydrocele, Hydrocele of Tunica Vaginalis
Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer
This population-based study will use provincial health administrative data to examine the risk of hospital admission for hydrocelectomy among males who underwent nephrectomy for kidney cancer, compared with males from the general…
- Conditions
- Hydrocele, Hydrocele of Tunica Vaginalis, Hydrocelectomy, Nephrectomy
- Trial name
- NCT07527637
- Testing
- Laparoscopic nephrectomy for kidney cancer, Open nephrectomy for kidney cancer
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Solid Tumor, Adult, Metastatic Solid Tumor
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab…
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
- Trial name
- NCT05856981
- Testing
- ADU-1805, Pembrolizumab
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 130 people
- Sponsor
- Sairopa B.V.
Clear Cell Renal Cell Carcinoma and Glioblastoma
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and…
- Trial name
- NCT07067905
- Testing
- 68Ga-XT771
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chinese PLA General Hospital
Urinary Bladder Neoplasms
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment…
- Trial name
- NCT06421142
- Testing
- imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Renal Cell Carcinoma
Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma
Adverse events (AEs) with Cabozantinib are frequent (about 40-67% of patients) and often lead to temporary treatment interruptions, dose reductions or permanent discontinuations, potentially reducing dose intensity and sustained…
- Trial name
- IMPACT (NCT07805122)
- Testing
- Intensified Monitoring of Pharmacology
- Where
- Italy
- Volunteers
- 216 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Clear Cell Renal Cell Carcinoma, Neoplasms
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
"This study is a phase 2, randomized study to evaluate the efficacy and safety of SLC-3010 in combination with axitinib versus axitinib monotherapy as second-line treatment in patients with locally advanced or metastatic clear…
- Conditions
- Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms, Malignant Neoplasm of Kidney, Except Renal Pelvis
- Trial name
- NCT07469683
- Testing
- SLC-3010 + Axitinib, Axitinib
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Yonsei University
Kidney Cancer, Renal Cancer
NSAID Use After Robotic Partial Nephrectomy
The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.
- Conditions
- Kidney Cancer, Renal Cancer, Renal Neoplasm
- Trial name
- No-PAIN (NCT05842044)
- Testing
- Ketorolac, Acetaminophen, Oxycodone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Miami
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Renal Cell Carcinoma (RCC), Radioembolization
Ablative Radioembolization of Renal Cell Carcinoma Trial
Renal cell carcinoma (RCC), the most common type of kidney cancer, is typically treated with surgery; however, there is no established therapy for patients who are not surgical candidates and who have tumours greater than 4.0 cm…
- Trial name
- ARRCC (NCT06642220)
- Testing
- Y-90 Selective Internal Radiation Therapy (SIRT)
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Derek W. Cool
Urothelial Cancer
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
- Trial name
- NCT07106762
- Testing
- Iza-bren, Cisplatin, Gemcitabine
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617)…
- Trial name
- NCT06004661
- Testing
- AAA617, 68Ga-PSMA-11
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Retention
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest.
- Trial name
- POUR (NCT03609580)
- Testing
- Tamsulosin - 1 week, Tamsulosin - 3 days
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Urology
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS…
- Trial name
- NCT07151560
- Testing
- 6 cycle RC48 and JS001, 12 cycle RC48 and JS001
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
Kidney Cancer, Renal Neoplasms
Tumor Rupture During Robotic Partial Nephrectomy
The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors.
- Trial name
- RUPTURE (NCT07065825)
- Testing
- robot-assisted partial nephrectomy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Prostate Cancer, Cervical Cancer
Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)
The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions.
- Conditions
- Prostate Cancer, Cervical Cancer, Bladder Cancer, Lung Cancer
- Trial name
- FASCINATE (NCT06691776)
- Testing
- online CBCT-guided adaptive radiation therapy using a new software
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.